We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




New Tool Developed to Identify Genetic Risk Factors

By LabMedica International staff writers
Posted on 13 Feb 2014
A new biological pathway-based computational model has been developed to identify underlying genetic connections between different diseases.

The model called the Pathway-based Human Phenotype Network (PHPN) mines the data present in large publicly available disease datasets to find shared single nucleotide polymorphisms (SNPs), genes, or pathways and expresses them in a visual form.

Geneticists at the Geisel School of Medicine at Dartmouth (Hanover, NH, USA) built a pathway-based human phenotype network (PHPN) of over 800 physical attributes, diseases, and behavioral traits, based on about 2,300 genes and 1,200 biological pathways. More...
Using genome-wide association study (GWAS) phenotype-to-genes associations, and pathway data from a free, open-source, curated and peer reviewed pathway database Reactome, they connected human traits based on the common patterns of human biological pathways, detecting more pleiotropic effects, and expanding previous studies from a gene-centric approach to that of shared cell-processes.

PHPN supports the integration of genomic and phenotypic data to uncover significant links between traits, attributes, and disease. This offers tremendous potential in identifying risk factors for certain diseases. At the same time, it can reveal important targets for therapeutic intervention. The automatic classification of phenotypes into “phenotype classes,” using the network’s topological modularity and a standard community detection algorithm, showed very promising results. Two traits that were connected in the PHPN but did not share any common associated genes or any clear-cut biological relationship were von Willebrand factor and FVIII levels (vWF) and hippocampal atrophy (HA).

Christian Darabos, PhD, the lead author of the study, said, “The intuitive network representation of the knowledge mined from several large-scale datasets makes the information accessible to anyone. It lies at the crossroads of computational genetics, systems biology, information theory, and network science. As a proof of concept, the PHPN has proven capable of identifying well-documented interactions, and many novel links that remain to be explored in depth. The PHPN is a hypothesis-generating tool, potentially capable of identifying yet uncharacterized common drug targets.” As a next step, the scientists will refine statistical methods, isolate networks for optimal results, and compare previous work on phenotype networks. The study was published on January 25, 2014, in the journal BioDataMining.

Related Links:

Geisel School of Medicine at Dartmouth
Reactome



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.